Brivekimig Clinical Trials (2026): 3 Studies for Focal Segmental Glomerulosclerosis & Glomerulonephritis Minimal Lesion
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
3 Brivekimig clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 3 indications (including Focal Segmental Glomerulosclerosis & Glomerulonephritis Minimal Lesion) and 376 total planned enrollment. 2 Brivekimig clinical trials are actively recruiting at 29 U.S. sites across 18 states. Most recent activity: NCT07170917 (Apr 2028).
Where to Participate: All Brivekimig Trial Sites in the U.S. (29 sites across 18 states)
Every actively recruiting Brivekimigtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | Investigational Site Number : 8400007 | Birmingham35233 | NCT06500702 | Map |
| AZ | Mayo Clinic in Arizona - Scottsdale- Site Number : 8400014 | Scottsdale85259 | NCT07170917 | Map |
| CA | Northridge Clinical Trials - Northridge- Site Number : 8400005 | Northridge91325 | NCT07170917 | Map |
| CA | Investigational Site Number : 8400015 | Orange92868 | NCT06500702 | Map |
| CA | Investigational Site Number : 8400012 | San Francisco94143 | NCT06500702 | Map |
| FL | FXM Clinical Research - Miami- Site Number : 8400017 | Miami33175 | NCT07170917 | Map |
| FL | FXM Clinical Research - Miramar- Site Number : 8400004 | Miramar33027 | NCT07170917 | Map |
| FL | Investigational Site Number : 8400025 | Tampa33612 | NCT06500702 | Map |
| GA | Advanced Medical Research - Atlanta- Site Number : 8400011 | Atlanta30342 | NCT07170917 | Map |
| GA | Emory Children's Center- Site Number : 8400020 | Atlanta30322 | NCT06500702 | Map |
| GA | Georgia Skin & Cancer Clinic- Site Number : 8400009 | Savannah31419 | NCT07170917 | Map |
| IL | Investigational Site Number : 8400014 | Chicago60611 | NCT06500702 | Map |
| IL | Investigational Site Number : 8400017 | Hinsdale60521 | NCT06500702 | Map |
| IA | The Iowa Clinic West Des Moines Campus- Site Number : 8400007 | West Des Moines50266 | NCT07170917 | Map |
| LA | Louisiana Dermatology Associates- Site Number : 8400006 | Baton Rouge70809 | NCT07170917 | Map |
| MI | Investigational Site Number : 8400010 | Ann Arbor48109 | NCT06500702 | Map |
| MN | Investigational Site Number : 8400019 | Edina55435 | NCT06500702 | Map |
| NV | Investigational Site Number : 8400018 | Las Vegas89107 | NCT06500702 | Map |
| NV | JDR Dermatology Research - Site number: 8400012 | Las Vegas89145 | NCT07170917 | Map |
| NM | Investigational Site Number: 8400028 | Albuquerque87109 | NCT06500702 | Map |
| NY | Investigational Site Number : 8400001 | New York10032 | NCT06500702 | Map |
| NC | Investigational Site Number : 8400021 | Chapel Hill27599 | NCT06500702 | Map |
| RI | Clinical Partners- Site Number : 8400002 | Johnston02919 | NCT07170917 | Map |
| SC | AMR Clinical South Strand, South Carolina- Site Number : 8400018 | Myrtle Beach29588 | NCT07170917 | Map |
| TX | Investigational Site Number : 8400024 | Dallas75204 | NCT06500702 | Map |
| TX | UT Southwestern Medical Center, Department of Dermatology- Site Number : 8400022 | Dallas75235 | NCT07170917 | Map |
| TX | Investigational Site Number : 8400005 | El Paso79902 | NCT06500702 | Map |
| TX | Investigational Site Number: 8400016 | Houston77054 | NCT06500702 | Map |
| UT | Alpine Research Association- Site Number : 8400008 | Layton84041 | NCT07170917 | Map |
Brivekimig clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | Total |
|---|---|---|---|
| P2 | 2 | 1 | 3 |
Recruiting Brivekimig clinical trials (2)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07170917 | BRIGHTENBrivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa | P2 | Hidradenitis Suppurativa | 208 | Nov 2025 |
| NCT06500702 | RESULTA Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease | P2 | Focal Segmental Glomerulosclerosis | 84 | Dec 2024 |
Brivekimig clinical trials by indication
Hidradenitis Suppurativa (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07170917 | BRIGHTEN | P2 | recruiting | Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa |
Type 1 Diabetes Mellitus (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06812988 | T1D OBTAIN | P2 | active not recruiting | Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule |
Focal Segmental Glomerulosclerosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06500702 | RESULT | P2 | recruiting | A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease |
Brivekimig pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| BRIGHTEN | NCT07170917 | P2 | recruiting | Hidradenitis Suppurativa | 208 | — |
| RESULT | NCT06500702 | P2 | recruiting | Focal Segmental Glomerulosclerosis | 84 | PMID 39899371 |
| T1D OBTAIN | NCT06812988 | P2 | active not recruiting | Type 1 Diabetes Mellitus | 84 | — |
All Brivekimig trials (3)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07170917 | BRIGHTEN | Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa | P2 | recruiting | 208 | Sanofi | Nov 2025 |
| NCT06500702 | RESULT | A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease | P2 | recruiting | 84 | Sanofi | Dec 2024 |
| NCT06812988 | T1D OBTAIN | Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule | P2 | active not recruiting | 84 | Sanofi | Feb 2025 |
Brivekimig clinical trials: frequently asked questions
- How many Brivekimig clinical trials are there?
- 3 Brivekimig clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants.
- Are Brivekimig clinical trials recruiting in 2026?
- Yes — 2 Brivekimig trials are actively recruiting in 2026, with 29 U.S. sites across 18 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Brivekimig being studied for?
- Brivekimig is being studied for Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Hidradenitis Suppurativa, Type 1 Diabetes Mellitus. The trials are grouped by indication on this page.
- What phase is Brivekimig in?
- Brivekimig clinical trials span 3 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Brivekimig clinical trials?
- The lead sponsor across the most Brivekimig trials is Sanofi. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Brivekimigas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: